These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24673265)

  • 1. Brief overview of selected approaches in targeting pancreatic adenocarcinoma.
    Samore WR; Gondi CS
    Expert Opin Investig Drugs; 2014 Jun; 23(6):793-807. PubMed ID: 24673265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stromal expression of SPARC in pancreatic adenocarcinoma.
    Neuzillet C; Tijeras-Raballand A; Cros J; Faivre S; Hammel P; Raymond E
    Cancer Metastasis Rev; 2013 Dec; 32(3-4):585-602. PubMed ID: 23690170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Ras-ERK pathway in pancreatic adenocarcinoma.
    Neuzillet C; Hammel P; Tijeras-Raballand A; Couvelard A; Raymond E
    Cancer Metastasis Rev; 2013 Jun; 32(1-2):147-62. PubMed ID: 23085856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising new therapies in advanced pancreatic adenocarcinomas.
    Kundranda M; Kachaamy T
    Future Oncol; 2014 Dec; 10(16):2629-41. PubMed ID: 25531049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New biomarkers and targets in pancreatic cancer and their application to treatment.
    Costello E; Greenhalf W; Neoptolemos JP
    Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agents targeting the Hedgehog pathway for pancreatic cancer treatment.
    Bisht S; Brossart P; Maitra A; Feldmann G
    Curr Opin Investig Drugs; 2010 Dec; 11(12):1387-98. PubMed ID: 21154121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twenty-one proteins up-regulated in human H-ras oncogene transgenic rat pancreas cancers are up-regulated in human pancreas cancer.
    Yabushita S; Fukamachi K; Kikuchi F; Ozaki M; Miyata K; Sukata T; Deguchi Y; Tanaka H; Kakehashi A; Kawamura S; Uwagawa S; Wanibuchi H; Suzui M; Alexander DB; Tsuda H
    Pancreas; 2013 Aug; 42(6):1034-9. PubMed ID: 23648844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
    Steele CW; Oien KA; McKay CJ; Jamieson NB
    Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer.
    Kato S; Kubota K; Shimamura T; Shinohara Y; Kobayashi N; Watanabe S; Yoneda M; Inamori M; Nakamura F; Ishiguro H; Nakaigawa N; Nagashima Y; Taguri M; Kubota Y; Goshima Y; Morita S; Endo I; Maeda S; Nakajima A; Nakagama H
    Cancer Sci; 2011 Nov; 102(11):2029-37. PubMed ID: 21812859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
    Strimpakos AS; Saif MW
    JOP; 2013 Jul; 14(4):354-8. PubMed ID: 23846926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. K-Ras4B/calmodulin/PI3Kα: A promising new adenocarcinoma-specific drug target?
    Nussinov R; Muratcioglu S; Tsai CJ; Jang H; Gursoy A; Keskin O
    Expert Opin Ther Targets; 2016 Jul; 20(7):831-42. PubMed ID: 26873344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene methylation in gastric cancer.
    Qu Y; Dang S; Hou P
    Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New therapeutic directions for advanced pancreatic cancer: cell cycle inhibitors, stromal modifiers and conjugated therapies.
    Matera R; Saif MW
    Expert Opin Emerg Drugs; 2017 Sep; 22(3):223-233. PubMed ID: 28783977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
    Zafar SF; Nagaraju GP; El-Rayes B
    Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A study of the suppressive effect on human pancreatic adenocarcinoma cell proliferation and angiogenesis by stable plasmid-based siRNA silencing of c-Src gene expression.
    Zhao X; Li DC; Zhao H; Li Z; Wang JX; Zhu DM; Zhou J; Cen JN
    Oncol Rep; 2012 Mar; 27(3):628-36. PubMed ID: 22200682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma.
    Weinberg BA; Yabar CS; Brody JR; Pishvaian MJ
    Oncology (Williston Park); 2015 Nov; 29(11):809-20, 886. PubMed ID: 26573060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
    Gomes EG; Connelly SF; Summy JM
    Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.